Navigation Links
Study could help improve gene therapy for heart disease, cancer
Date:10/12/2011

MAYWOOD, Ill. -- A Loyola University Chicago Stritch School of Medicine study could lead to improved gene therapies for conditions such as heart disease and cancer as well as more effective vaccines for tuberculosis, malaria and other diseases.

Senior author Christopher Wiethoff, PhD, and colleagues report their findings in the October issue of the Journal of Virology. Editors spotlighted the report as one of the "articles of significant interest." Journal of Virology is the leading journal of the study of viruses.

The study involved a virus that causes the common cold, called adenovirus. Scientists have been trying to use a version of this virus as a delivery vehicle for gene therapies and vaccines. (The virus is not able to reproduce and cause disease.) Administering this virus to patients causes an inflammatory reaction, which can be a double-edged sword: The reaction aids in the use of the virus in vaccines but limits its use for gene therapies.

In gene therapy, one or more desired genes are introduced into the adenovirus, which is then administered to the patient. Once in the body, the virus enters targeted cells and delivers the desired genes. In heart disease patients, for example, the virus delivers genes that trigger the growth of new blood vessels in damaged heart muscle. However, when the adenovirus enters a cell to deliver a desired gene, it causes an inflammatory immune response. In extreme cases, this can endanger the patient. In one highly publicized case, a University of Pennsylvania gene therapy patient named Jesse Gelsinger died from a massive immune response triggered by the use of the adenovirus.

In vaccines, the adenovirus delivers one or more genes. These genes instruct cells to produce a specific protein, which is normally part of the targeted pathogen. This protein, in turn, jump-starts the patient's immune system to attack a specific pathogen, such as the bacterium that causes tuberculosis or the parasite that causes malaria. Here, the inflammatory immune response has the beneficial effect of revving up the immune system to attack germs.

The Loyola study provides new insights into how the adenovirus triggers an immune response. The study involved immune cells from humans and mice. Researchers discovered how cells sense the adenovirus as it enters a cell. This recognition, in turn, triggers the immune response. The finding could help researchers tailor the adenovirus so that it causes less of an immune response in gene therapy applications and an enhanced immune response in vaccines.

"These results will help with future studies of innate immune responses to adenovirus," Wiethoff and colleagues wrote. "Additionally, our understanding of this process could allow us to either enhance or attenuate [weaken] the innate immune response to adenovirus to generate novel vectors for gene therapy and vaccination."


'/>"/>

Contact: Jim Ritter
jritter@lumc.edu
708-216-2445
Loyola University Health System
Source:Eurekalert

Related medicine news :

1. Where Folks Live Plays Role in Health Disparities: Study
2. Many on Medical Guideline Panels Have Conflicts of Interest: Study
3. National study finds vitamin E supplement may increase prostate cancer risk
4. Study Suggests Origins of Pregnancy-Linked High Blood Pressure
5. Lasers Safe for Removal of Pacemaker Wires in Elderly: Study
6. OU professors awarded $2.8 million for 4-year study on biodiversity in warmer climates
7. Direct-to-Consumer Gene Tests Cause Little Anxiety: Study
8. Natural processes can limit spread of arsenic in water, says study
9. Case Western Reserve receives prestigious $5.4 million grant to study esophageal cancer
10. Mayo Clinic wins grant to study ethics of sharing genetic test results with relatives
11. UIC awarded $14 million to study tobacco pricing and media
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/26/2017)... , ... September 26, 2017 , ... ... today announced the Atmosera Release Management as a Service (RMaaS) to ... or PaaS environments. Customers include any companies, e-tailers, and web development agencies who ...
(Date:9/26/2017)... ... 26, 2017 , ... Two innovative companies are bringing to ... it is scientifically proven as well: ABAlife™. Euromed SA, a leading manufacturer of ... agreement with BioTherapeutics Inc. for patented technology for absiscic acid (ABA). , ...
(Date:9/26/2017)... ... September 26, 2017 , ... ... John R. Elliott HERO Campaign for Designated Drivers proudly announced the winners of ... Thirty-one local bars and restaurants took on the challenge of competing in three ...
(Date:9/26/2017)... ... September 26, 2017 , ... Data Integrity: , The Key ... Dec. 5-6, 2017 – Arlington, VA, http://www.fdanews.com/fdadataintegrity , Consider ... the firm’s electronic records may not be trustworthy and reliable … a more detailed ...
(Date:9/26/2017)... ... September 26, 2017 , ... ... the Chair of the Leg, Ankle, and Foot Section of the Department of ... fellowship trained orthopedic surgeon at Hackensack UMC performing total ankle replacements. Because of ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... --  PDI , a leader in infection prevention products ... session focused on the role of chlorhexidine gluconate (CHG) ... 2017 Annual Scientific Meeting of the Association for Vascular ... Phoenix Convention Center in ... also feature PDI,s Prevantics® Device Swab as ...
(Date:9/6/2017)... Eli Lilly and Company (NYSE: LLY ) ... and lasmiditan, two investigational treatments for migraine, at the ... place Sept. 7-10 in Vancouver . ... from an open-label study evaluating the safety and effectiveness ... mg) for the prevention of migraine. Galcanezumab is a ...
(Date:9/5/2017)... Sept. 5, 2017  Xyntek Inc. has announced another milestone in their continued ... office to meet the growing demands of customer engagements regionally.  ... Xyntek's new Midwest office is located at 318 West Adams Street, ... ... regionally. ...
Breaking Medicine Technology: